论文部分内容阅读
目的:探讨EGFR和EGFRvⅢ在人乳腺癌及乳腺良性增生性疾病中的表达及临床意义。方法:应用Supervi-sionTM免疫组化方法检测30例乳腺良性增生性病变、病变旁及55例乳腺癌、癌旁和转移淋巴结组织的EGFR、EGFRvⅢ的表达。结果:EGFR在乳腺癌表达72.7%,癌旁29.1%,转移淋巴结58.3%(χ2=5.326,P=0.021);EGFRvⅢ在乳腺癌表达52.7%,癌旁1.8%,转移淋巴结45.8%(χ2=4.718,P=0.030)。EGFR表达与病理分级(χ2=11.840,P=0.002)、转移淋巴结数目(χ2=13.715,P=0.000)、ER阴性(χ2=10.785,P=0.007)、PR阴性(χ2=4.727,P=0.031)相关;EGFRvⅢ与病理分级(χ2=5.280,P=0.024)、有无远处转移(χ2=5.612,P=0.019)、淋巴结转移数目(χ2=4.464,P=0.038)、ER阴性(χ2=3.960,P=0.049)、PR阴性(χ2=17.517,P=0.000)和c-erbB-2阳性(χ2=7.424,P=0.005)相关。结论:EGFR、EGFRvⅢ过度表达可能与乳腺癌发生发展密切相关,EGFRvⅢ有望作为预测乳腺癌临床预后候选基因之一。
Objective: To investigate the expression and clinical significance of EGFR and EGFRv Ⅲ in human breast cancer and benign breast hyperplasia. Methods: The expression of EGFR and EGFRvⅢ in 30 cases of benign and malignant breast lesions, adjacent to the lesions and 55 cases of breast cancer, paracancer and metastatic lymph nodes were detected by Supervi-sionTM immunohistochemical method. Results: The expression of EGFR was 72.7% in breast cancer, 29.1% in breast cancer and 58.3% in metastatic lymph node (χ2 = 5.326, P = 0.021). The expression of EGFRvⅢ was 52.7% in breast cancer, 1.8% in paracancer and 45.8% in metastatic lymph node , P = 0.030). The number of metastatic lymph nodes (χ2 = 13.715, P = 0.000), ER negative (χ2 = 10.785, P = 0.007) and PR negative (χ2 = 4.727, P = 0.031) (Χ2 = 5.612, P = 0.019), the number of lymph node metastasis (χ2 = 4.464, P = 0.038), ER negative (χ2 = 3.960, P = 0.049), PR negative (χ2 = 17.517, P = 0.000) and c-erbB-2 positive (χ2 = 7.424, P = 0.005). Conclusion: EGFR and EGFRv Ⅲ overexpression may be closely related to the development of breast cancer. EGFRv Ⅲ may be one of the candidate genes for predicting the prognosis of breast cancer.